Articles tagged with Cancer Patients
A recent study by MSK Kids researchers found that pediatric cancer patients do not have a higher risk of COVID-19 infection or morbidity. In fact, only 95% of children with cancer infected with COVID-19 had mild symptoms and did not require hospitalization.
Researchers with the ECOG-ACRIN Cancer Research Group presented new findings on breast cancer treatment trials, including TAILORx and NCI-MATCH. The studies found that women under 40 are at risk for early discontinuation of hormone therapy, and insurance status plays a key role in adherence to adjuvant hormone therapy.
A new study reveals that children with cancer in New York are disproportionately affected by COVID-19, with a higher risk of severe illness. The research highlights the importance of prioritizing vaccine administration and infection control measures to protect these vulnerable patients.
The trial found that reduced postoperative radiation therapy in intermediate-risk patients with HPV+ oropharynx squamous cell carcinoma is safe and effective, with very good oncologic outcomes. Patients at low risk had favorable two-year progression-free survival without postoperative therapy.
Primary care clinicians perceive their role in caring for cancer survivors, but approaches vary widely. Researchers recommend coordinating care between primary care and oncologists to address complex needs.
The Cancer IO project aims to drive creation of a Finnish IO ecosystem and national IO growth strategy, boosting business competitiveness and individualization of care. With 10 million euros funding, the project will support top-level research and development of cancer immunotherapy treatments.
A new saliva test has detected early throat cancer in a person with no symptoms, highlighting a potential breakthrough in cancer screening. The test identified HPV-DNA in the saliva of an infected individual, allowing for early removal of the affected tonsil through surgery.
A clinical trial found that olanzapine significantly improved patient quality of life by reducing nausea and vomiting scores. The study showed that patients who received olanzapine reported less vomiting, better appetite, and better well-being compared to those who received a placebo.
A recent analysis of published studies found that many cancer survivors lack awareness of financial toxicity and are unprepared for its impacts. Despite coping mechanisms, they still have unmet needs for managing financial toxicity.
Research reveals that small chromosomes have a higher rate of DNA double-strand breaks to ensure proper recombination and segregation. This 'boost' helps explain how small chromosomes punch above their weight, ensuring recombination on every chromosome.
A new study discovered that tumor markers for various cancers also predict heart failure severity and mortality in patients with heart failure. The study found strong correlations between cancer markers and known heart failure indicators, suggesting a relationship between cancer and cardiovascular disease.
A recent survey found that enrollment in supportive oncodermatology programs is associated with improved quality of life scores among cancer patients. The study, published in the Journal of Drugs in Dermatology, highlights the benefits of these interventions on patient dermatologic health and overall well-being.
Researchers analyzed ATAC-seq data from 404 cancer patients to correlate chromatin accessibility with tumor characteristics, age, sex, and survival rates. The study found that chromatin accessibility on the X chromosome is strongly dependent on patient sex, but not on age or tumor stage.
A study of over 12,000 patients found that those with abnormally small red blood cells had a higher risk of cancer. The research suggests that microcytosis could be an early indicator of various cancers.
A large study of cancer patients with COVID-19 reveals a dramatically high case-fatality rate of 28%, significantly higher than the overall US mortality rate. The study emphasizes the importance of preventing cancer patients from contracting COVID-19 and closely monitoring for dangerous symptoms.
Scientists at Huntsman Cancer Institute have discovered the protein LEM2 plays two vital roles during cell division: sealing damaged DNA and recruiting factors that disassemble fibers separating DNA sets. This process may be critical for understanding cancer development and progression.
A new form of local chemotherapy using a mitomycin-containing reverse thermal gel has been shown to be effective in treating low-grade upper tract urothelial cancer, allowing patients to keep their kidney. The treatment has a high complete response rate and is associated with manageable side effects.
The FDA has approved encorafenib in combination with cetuximab for patients with advanced BRAF-mutated colorectal cancer. This new treatment is the result of DNA-guided personalized cancer treatment research by the SU2C-Dutch Cancer Society team.
Researchers at MD Anderson Cancer Center and Ipsen Biopharmaceuticals have developed a novel drug, IPN60090, a glutaminase inhibitor for lung and ovarian cancers. The Phase I clinical trial shows promising results, particularly for patients with KEAP1/NRF2 mutations or low ASNS levels.
Prolgolimab, a Russian original PD-1 inhibitor, has been approved for the treatment of advanced melanoma. The drug demonstrated significant antitumor activity and manageable safety in a phase II study, with 42 out of 126 patients experiencing an objective response.
Research highlights continued support for immunotherapy approaches to pediatric ALL and lung cancer, as well as progress in Cancer Interception. The studies aim to identify genes that may be responsible for immune suppression or activation in Bronchial premalignant lesions.
A nanomedicine expert proposes a cancer care model for managing COVID-19, focusing on early detection, regular monitoring, and targeted treatment. This approach could improve patient outcomes by providing systematic management of the pandemic.
A recent study found pediatric cancer trial enrollment decreased from 40-70% in the 1990s to 19.9% in the current study. This decline is partly attributed to improved treatments for common childhood cancers, shifting focus to rarer and higher-risk cancers.
A new targeted drug, adavosertib, has demonstrated strong activity against uterine serous carcinoma (USC), a hard-to-treat form of the disease. In nearly one-third of patients, tumors shrank in response to the treatment.
A nationwide trial tests video counseling to help cancer patients quit smoking, addressing a significant public health concern. The study aims to provide evidence for tobacco treatment as standard care in community hospitals and clinics.
Researchers have discovered a gene signature, USC73, that can identify women with rare and aggressive uterine serous carcinoma who are unlikely to respond to standard chemotherapy. The high USC73 score is associated with poor patient survival, cancer cell proliferation, and low rates of complete response to treatment.
A study by King's College London found that cancer patients referred by GPs with suspected cancer had lower mortality rates and were more likely to be diagnosed at an earlier stage for breast, lung, and prostate cancer. Early GP referrals have made a significant impact in improving cancer outcomes in the NHS.
The NCCN Guidelines for Patients are among the most trustworthy resources for patients and caregivers seeking information on prostate cancer. The guidelines, written in an easy-to-learn format, provide essential information on diagnosis and treatment.
A study found that patients experienced higher rates of infections in the years leading up to a cancer diagnosis compared to those without cancer. The researchers discovered an association between specific infections and increased risk of certain types of cancer.
The seven European cancer centers of Cancer Core Europe have shared their experiences and measures taken to adapt to the COVID-19 pandemic. They emphasize the importance of adapting clinical activities, communication with patients, qualified personnel, and regional collaborations to ensure continuity in cancer care.
A new imaging technique combining high-resolution imaging with quantitative measurement of tissue elasticity can detect cancer within resected margins of breast-conserving surgery. The study found QME to have high sensitivity and specificity for detecting cancer, reducing the need for additional surgeries.
Researchers at Moffitt Cancer Center have identified the PERK protein as a critical molecular pathway controlling immunosuppression in tumor cells. By targeting PERK, cancer patients may experience reactivation of their immune system and enhanced effectiveness of immunotherapy treatments.
A recent study highlights the difficulties healthcare providers face when caring for cancer patients during a pandemic. The authors discuss strategies to mitigate these challenges and improve patient outcomes in Italy during the COVID-19 epidemic.
A clinical trial found that immunotherapy significantly slowed the worsening of urothelial cancer when given after platinum-based chemotherapy, with a 60% longer time to cancer progression compared to the control group. The switch maintenance immunotherapy approach is expected to become a standard of care for metastatic bladder cancer.
Patients with lung cancer in China who knew their diagnosis survived longer than those who did not, with a median survival time of 18.33 months versus 8.77 months. The study suggests that full disclosure of cancer diagnoses can benefit patients in the long term with proper communication and support.
A new study published in Cancer Research found that Indigenous American ancestry is associated with a greater incidence of HER2-positive breast cancer in Latinas. The study analyzed data from over 1,300 patients and found that women with higher proportions of IA ancestry were more likely to develop HER2-positive tumors.
A Phase II study found that 93% of patients with relapsed or refractory mantle cell lymphoma responded to CD19-targeting CAR T-cell therapy KTE-X19, with 67% achieving a complete response. The estimated progression-free survival and overall survival were 61% and 83%, respectively.
A genetic defect in 15% of children with medulloblastoma leads to disrupted protein production and metabolism, increasing the risk of cancer. The study identifies a new hereditary cause of medulloblastoma, which could lead to more effective treatment options for affected families.
During the COVID-19 outbreak in China, cancer patients underwent enhanced care measures to minimize SARS-CoV-2 transmission risk. These measures included strict infection control protocols and isolation procedures.
A Phase II trial found patients with metastatic castration-resistant prostate cancer who showed active T-cell responses in their tumors experienced prolonged survival after ipilimumab treatment. Researchers identified biomarkers associated with improved responses, including higher T-cell density and interferon-γ signaling.
A study found that physicians use varying strategies to address patients' worry about thyroid cancer, with some telling them it's a 'good cancer.' However, this approach may not be effective in alleviating worry. The research emphasizes the need for physician education and intervention to better support patients.
The study found that Medicaid expansions in states that adopted the Affordable Care Act were linked to a greater percentage of patients with localized head and neck cancer diagnosed at an early stage. Timely treatment led to improved survival rates for these patients. The researchers hope their findings will inform policy makers.
A new study found that cancer treatment with immune checkpoint inhibitors is associated with an increased risk of thyroid dysfunction, affecting up to 40% of patients. The type of cancer and specific combination of medications used can impact the likelihood of developing thyroid problems.
The Caravaggio study found that oral apixaban is at least as effective as dalteparin in preventing recurrent venous thromboembolism and major bleeding events in patients with cancer. The trial showed no significant difference in the risk of major bleeding, including gastrointestinal cancers, between the two treatments.
Researchers at the University of Virginia have identified inherited genetic variations that can predict patient outcomes and improve treatment success. By analyzing vast amounts of genetic data, doctors can now tailor treatments to individual patients' needs and genetic makeup.
A new blood test has been developed to detect a wide range of cancers, including breast, colorectal, and pancreatic cancer, with an accuracy rate of 99.3%. The test uses next-generation sequencing to analyze DNA methyl groups, which can indicate the presence of cancer.
A phase II clinical trial found that stereotactic ablative radiation (SABR) slowed disease progression in a subset of men with limited spread of prostate cancer. SABR treatment was associated with an expanded population of T cells, suggesting a full-body immune system response to their cancers.
Researchers at MD Anderson Cancer Center developed a combination therapy that reprograms effector T cells into persistent central memory T cells capable of self-renewal and effective cancer cell killing. This approach addresses the persistence challenge in cellular therapies, increasing their effectiveness.
Researchers estimated SARS-CoV-2 infection rate in cancer patients at a Wuhan hospital, revealing potential risks and health concerns. The study found that SARS-CoV-2 transmission occurred among cancer patients, emphasizing the need for enhanced precautions.
In a phase I study, fam-trastuzumab deruxtecan-nxki (Enhertu) demonstrated clinical activity in patients with non-breast/non-gastric cancer types with HER2 overexpression or mutation. The overall objective response rate was 28.3 percent, with greatest response rates for NSCLC and HER2-mutant NSCLC.
A new study found that taking higher daily step counts is associated with a lower risk of death from all causes. The study tracked over 4,800 U.S. adults and found that those who took 8,000 steps per day had a 51% lower risk compared to those who took 4,000 steps.
A study found that myelin, the protective coating of nerve cells, is dynamic and not inert as traditionally believed. This discovery has implications for treatment of multiple sclerosis and chemobrain, a type of myelin damage caused by chemotherapy drugs.
Researchers discovered that cancer cells induce lung tissue inflammation, releasing signals CXCL9 and CXCL10, which aid metastasis growth. The interaction between detached cancer cells and fibroblasts is crucial for metastatic colonization.
Researchers used AI to predict tumor sensitivity to three systemic cancer therapies in patients with advanced NSCLC. The models achieved an AUC of 0.77, 0.67, and 0.82 for nivolumab, docetaxel, and gefitinib, respectively.
A Phase II study found pembrolizumab to be effective in treating four rare cancer types with acceptable toxicity profiles. The treatment resulted in a median non-progression rate of 28% at 27 weeks, with complete response rates varying between 31-43% for each cancer type.
A phase 2 clinical trial conducted by the National Cancer Institute found that selumetinib improved outcomes for children with neurofibromatosis type 1 (NF1), shrinking inoperable tumors and reducing pain. The treatment also led to clinically meaningful improvements in quality of life, strength, and range of motion.
A study confirms racial disparities in treatment outcomes for pediatric brain cancer patients, with Black and Hispanic patients facing poorer prognoses after diagnosis and treatment, regardless of stage at diagnosis.
Researchers found that immunosuppressive therapy does not increase the occurrence or recurrence of vulvar or vaginal cancer in women with IBD, but an earlier onset was reported. Lymphomas were also found in some patients, which is rare in the genital tract.
A study published in Nature identified distinct microbial signatures associated with specific cancer types, including colon cancer and prostate cancer. Machine learning models trained on these signatures were able to distinguish between cancer patients and healthy individuals with high accuracy.
A University of Colorado Cancer Center study found that African American patients were half as likely as non-Hispanic whites to receive PET-CT imaging for non-small cell lung cancer, while Hispanics received it 70% as frequently. This disparity may be due to limited access to specialized imaging equipment and unconscious bias.